Aurobindo Pharma is set to commence manufacturing of a long-acting injectable HIV treatment, marking a pivotal move in the evolving landscape of antiretroviral therapies. This development underscores the company’s ambition to advance beyond conventional generic formulations and deepen its foothold in complex, high-value drug segments. By investing in innovative delivery systems that reduce dosing frequency, Aurobindo aims to address critical adherence challenges in HIV care while capturing emerging global demand.